Name: Latest research reports of Divi's Laboratories Ltd. authored by BOB Capital Markets Ltd. and published by - Trendlyne research reports.
Item: Divi's Laboratories Ltd.
Rating: 1
Author: BOB Capital Markets Ltd.

Divi's Laboratories Ltd.

NSE: DIVISLAB | BSE: 532488 | ISIN: INE361B01024 | Industry: Pharmaceuticals
| Expensive Performer

6573.0000 12.00 (0.18%)

NSE Oct 15, 2025 15:46 PM

32.65% Gain from 52W Low

Volume: 462.1K

Divi's Laboratories Ltd.

25 May 2024

6573.00

0.18%

Divi's Labs (SELL): Strong quarter; rich valuations

Sell: Divi's Laboratories Ltd.

BOB Capital Markets Ltd.

DIVI delivered a strong quarter with all round beat. EBITDA/PAT beat Bloomberg consensus estimate by 20% each

Divi's Laboratories .. has an average target of 6414.33 from 6 brokers.